Presentation is loading. Please wait.

Presentation is loading. Please wait.

Building a Europe of Knowledge Towards the Seventh Framework Programme 2007-2013 Medical and Public Health Research DG Research European Commission Brussels.

Similar presentations


Presentation on theme: "Building a Europe of Knowledge Towards the Seventh Framework Programme 2007-2013 Medical and Public Health Research DG Research European Commission Brussels."— Presentation transcript:

1 Building a Europe of Knowledge Towards the Seventh Framework Programme Medical and Public Health Research DG Research European Commission Brussels Medical and Public Health Research DG Research European Commission Brussels

2 Aims: FP7 : Towards the world’s leading research area Investment in world class research Build on and further efforts of FP6 – towards a knowledged based economy and society

3 New FP7 FP7: What’s new? Main elements:   Duration increased to seven years   Annual average budget increase €4.47 (FP6) to €7.22 billion (FP7)   Frontier research (~ €1.1 billion per year)   New structure: Cooperation – Ideas – People – Capacities   Flexible funding schemes   Joint Technology initiatives   Simpler procedures   Outsourcing

4 Cooperation Ideas (European Research Council) Ideas (European Research Council) SpecificProgrammes: People Capacities FP7: Structure

5 Total FP7 budget: € 54,582 billion *of which Health 6,1 Cooperation 32,413* 7,51 Ideas People 4,75 Capacities 4,097 Euratom 4,06 JRC (EC) 1,751 FP7 Budget

6 Cooperation Ten Themes: 1.Health 2.Food, agriculture and fisheries, biotechnology 3.Information and communication technologies 4.Nanosciences, nanotechnologies, materials and new production technologies 5.Energy 6.Environment (including climate change) 7.Transport (including aeronautics 8.Socio-economic sciences and humanities 9.Space 10.Security

7 Objectives: Health   Improving the health of European citizens   Increasing the competitiveness of European health-related industries   Addressing global health issues including emerging epidemics

8 Rationale:   Sequencing of human genome and recent advances in post-genomics  to integrate vast amounts of data   Translational research  to bring knowledge into the clinic   Clinical research  international multi-centre trials   Reinforce health policy-driven research  comparison of the national policies   Strong EU-based biomedical research  strengthen competitiveness of industries and SMEs Health

9 Biotech, tools, technology Translational research Public Health Research Health Three pillars:   Biotechnology, generic tools and technologies for human health   Translating research for human health   Optimising the delivery of health care to European citizens Health

10 Health Pillar 1: Biotechnology, generic tools and medical technologies for human health   High-throughput research   Detection, diagnosis and monitoring   Predicting suitability, safety and efficacy of therapies (incl. alternatives to animal testing)   Innovative therapeutic approaches and interventions Biotech Translational Public Health Health

11 Health Pillar 2: Translating research for human health   Integrating biological data and processes: large-scale data gathering, systems biology   Research on the brain and related diseases, human development and ageing   Translational research in infectious diseases: drug resistance, HIV/AIDS, malaria, tuberculosis, hepatitis, new and re-emerging epidemics, etc.)   Translational research in major diseases: cancer; cardiovascular disease; diabetes/obesity; rare diseases; other chronic diseases (e.g. rheumatic, respiratory, musculo-skeletal diseases and arthritis) Biotech Translational Public Health Health

12 Health Pillar 3: Optimising the delivery of health care to European citizens Translating the results of clinical research outcome into clinical practice, including better use of medicines Quality, efficiency and solidarity of health systems including transitional health systems (i.e. health systems that are currently under reform) Enhanced health promotion and disease prevention Biotech Translational Public Health Health

13 Cooperation Ideas People Capacities Collaborative Research Funding schemes:   Collaborative Projects  Multi-partner, multi-national research projects   Networks of Excellence  integrating activities in a given field   Coordination and Support Actions  Small scale coordination and support activities  Specific topics, in particular SMEs  Based on calls for proposals

14 INCO / ERA NET International Cooperation Coordination of Non-Community Research Programmes Enhance participation of third countries Enhance participation of third countries  specific actions  specific actions  through specific topics in thematic areas  through specific topics in thematic areas ERA NETs ERA NETs  implementing public research programmes  implementing public research programmes  not necessarily within priorities  not necessarily within priorities Article 169 Article 169 Cooperation Ideas People Capacities

15 Joint Technology Initiatives  Arising from European Technology Platforms  In fields of major European public interest  “Strategic Research Agenda” defined by stakeholders  Specific implementation structure and modus operandi New FP7 Innovative Medicines Initiative: Innovative Medicines Initiative: Accelerate development of safe and more effective medicines by joint public-private collaborations Accelerate development of safe and more effective medicines by joint public-private collaborations Cancer - Brain disorders - Inflammatory diseases – Metabolic diseases - Infectious diseases Cancer - Brain disorders - Inflammatory diseases – Metabolic diseases - Infectious diseases Cooperation Ideas People Capacities

16 New FP7 Principles of the European Research Council Investigator – driven frontier research in all research areas Investigator – driven frontier research in all research areas Europe-wide competitive funding structure Europe-wide competitive funding structure  Excellence as sole criterion  Excellence as sole criterion Individual independent teams Individual independent teams Grants (100% reimbursement) Grants (100% reimbursement) Two funding schemes: Two funding schemes:  Starting Independent Researcher scheme  Advanced Investigator scheme Cooperation Ideas People Capacities

17 Marie Curie Actions Overall scope: Human resource development in R&D in Europe   Initial training of researchers  Marie Curie Networks   Life-long training and career development  Individual Intra-European Fellowships  Co-financing of reg./nat./internat. Programmes   Industry-academia pathways and partnerships  Industry-Academia Knowledge–sharing Scheme*   International dimension  Outgoing & Incoming International Fellowships*  International Cooperation Scheme  Reintegration grants   Specific actions  Mobility and career enhancement actions  Excellence awards * Open to third-country nationals Cooperation Ideas People Capacities

18 Capacities Research infrastructures Research infrastructures Research for the benefit of SMEs Research for the benefit of SMEs  Small groups of SMEs  Small groups of SMEs  SME associations/groupings  SME associations/groupings Regions of Knowledge Regions of Knowledge Research Potential Research Potential Science in Society Science in Society Activities of International Cooperation Activities of International Cooperation Coherent development of policies Coherent development of policies Activities: Cooperation Ideas People Capacities

19 Research Infrastructures Support to existing research infrastructures Support to existing research infrastructures Support to new research infrastructures Support to new research infrastructures  Six relevant to Health Research  Six relevant to Health Research ► EATRIS (Eu. Adv. Transl. Res. Infrastr. in Medicine) ► EATRIS (Eu. Adv. Transl. Res. Infrastr. in Medicine) ► European Bio-banking and Biomolecular Resources ► European Bio-banking and Biomolecular Resources ► INFRAFRONTIER ► INFRAFRONTIER ► Infrastructure for Clinical Trials and Biotherapy Facilities ► Infrastructure for Clinical Trials and Biotherapy Facilities ► Integrated Structural Biology Infrastructure ► Integrated Structural Biology Infrastructure ► Upgrade of European Bio-Informatics Infrastructure ► Upgrade of European Bio-Informatics Infrastructure  Exploratory awards for design studies Cooperation Ideas People Capacities

20 Simplification of procedures Objective: Rationalisation and Rationalisation and streamlining of streamlining of procedures procedures   Lighter submission, evaluation, reporting   Reducing a priori controls   Streamlining the selection process  Reduced ‘time to project start’   Exploring new modes of funding  Greater use of lump-sum and flat-rate financing schemes   Simplifying the costs-based system  Simplified cost-reporting models used for FP6 Cooperation Ideas People Capacities

21 Minimum conditions: Rules for participation   3 independent participants from 3 different Member States (MS) or Associated countries (Ac)   Additional conditions can be established by the work programme (WP) or specific programme (SP)   Frontier research actions (ERC): at least 1 legal entity established in a MS or Ac   Coordination and support actions and actions in favour of training and career development of researchers – minimum of 1 legal entity   Collaborative projects addressing the participation of international cooperation partner countries (INCO) minimum is 4 participants of which 2 in MS or Ac and 2 in INCO countries   Participation of international organisations and participants from third countries possible if in addition to minima

22 Submission and Evaluation: Rules for participation   Calls for proposals as a rule   Evaluation criteria established in the Rules for Participation   Transparent, fair and impartial evaluation with help of independent experts   Commission - to adopt and publish rules for proposal submission, evaluation, selection and award   Commission - to adopt and publish rules to ensure consistent verification of legal status and financial capacity of participants

23 Evaluation criteria: Rules for participation   Eligibility  deadlines (electronic submissions only).  minimum number of participants/countries.  completeness of proposal (NB: page limits).  relevance to the objectives of the work programme.  Financial thresholds.   1. Scientific Excellence  Quality of objectives and concept, state of the art, methodology.   2. Impact  Expected impact as set out in work programme, dissemination activities and IPR management.   3. Implementation  competence of partners, quality of the consortium (complementarity), managerial approach, allocation and justification of resources (budget, staff, equipment).

24 Implementation: Rules for participation   Participants implement work jointly and carry out work of a defaulting partner unless the Commission relieves them of that obligation   No more financial collective responsibility ≠ FP6 Instead: establishment of a participant guarantee fund to cover risks   Consortium agreements obligatory unless exempted by call for proposals   Changes in consortium membership possible

25 Funding rates: Rules for participation   Cost reporting models eliminated !   Up to 50% of eligible costs: 1. 1.R&D activities: Exceptions:   Public bodies   Secondary and higher education establishments   Non-profit research organisations   SMEs  all of which up to 75% 2. 2.Demonstration activities: up to 50%   Up to 100%:   Other activities (e.g. Management)   Training and career development actions   Frontier research actions   Coordination and support actions

26 FP7 Timeline  April 2005  Commission’s proposal  April 2005  Commission’s proposal  April 2006  Approval Financial Perspective  April 2006  Approval Financial Perspective  Dec 2006  Adoption of FP7  Dec 2006  Adoption of FP7  Dec 2006  Decision specific programmes  Dec 2006  Decision specific programmes  Dec 2006  First calls for proposals  Dec 2006  First calls for proposals  Feb 2007  Launch FP7  Feb 2007  Launch FP7

27 First WPs in CVD area Vascular remodelling in atherosclerosis; aneurysmal disease Vascular remodelling in atherosclerosis; aneurysmal disease Combating stroke Combating stroke Congenital heart diseases Congenital heart diseases Pharmacogenomic approaches CVD Pharmacogenomic approaches CVD Cell therapies for the treatment of heart ischemia Cell therapies for the treatment of heart ischemia Organ imaging in CVD Organ imaging in CVD

28 Information  Seventh Framework Programme:  EU research:  Research programmes and projects:  Latest info on IMI:  Latest info on ERC:  To register as an Expert for FP7: https://cordis.europa.eu/emmfp7

29 EU – Member States (n = 27) Candidate/Accession countries Croatia Turkey Countries associated with the FP Iceland Israel Norway Switzerland Thank you for your attention!


Download ppt "Building a Europe of Knowledge Towards the Seventh Framework Programme 2007-2013 Medical and Public Health Research DG Research European Commission Brussels."

Similar presentations


Ads by Google